Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Download All
Learn how global experts are leveraging the latest data on antibody–drug conjugates targeting HER2, HER3, and TROP2 to optimally manage patients with NSCLC! Download slides, watch the on-demand Webcast, and listen to a podcast adapted from the live expert Webinar on new developments from ELCC 2021, then review the most important data on lung cancer from ASCO 2021.
Egbert F. Smit, MD, PhD
Program Director
David Planchard, MD, PhD
Egbert F. Smit, MD, PhD
Helena A. Yu, MD

Downloadable Slidesets

Download these slides from a CCO Live Webinar to review the latest clinical data novel antibody-drug conjugates for the treatment of NSCLC.

Egbert F. Smit, MD, PhD Released: April 8, 2021

Download these slides from a live CCO Webinar to review the latest clinical trial data on ADCs in NSCLC, including activity in HER2-amplified or mutant lung cancers, as well as in HER3-expressing, EGFR-mutatant NSCLC.

Helena A. Yu, MD Released: April 8, 2021

Download these slides from a live CCO Webinar to review the latest clinical trial data on anti–TROP-2, anti-CEACAM, and anti–c-MET ADCs in lung cancer, including ongoing trials evaluating ADC combinations with immunotherapy or third-generation EGFR TKIs.

David Planchard, MD, PhD Released: April 8, 2021

Download this short summary slideset summarizing clinical trial data presented at a live CCO Webinar featuring expert discussion on the increasing role of antibody-drug conjugates in advanced NSCLC.

David Planchard, MD, PhD Egbert F. Smit, MD, PhD Helena A. Yu, MD Released: April 14, 2021

On-Demand Webcast

Watch this on-demand webcast from a live webinar where experts discuss the latest clinical trial data and their thoughts on the potential for antibody–drug conjugates in the care of patients with advanced NSCLC.

Egbert F. Smit, MD, PhD
Program Director
David Planchard, MD, PhD Helena A. Yu, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 23, 2021 Expired: April 22, 2022

ClinicalThought

Are antibody drug conjugates a true targeted therapy for NSCLC? Read my thoughts on why I believe ADCs are a great therapeutic option for patients with advanced NSCLC.

Helena A. Yu, MD Released: April 20, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue